# TJ Biopharma Co., Ltd. clinical trials: 20 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 20 trials with TJ Biopharma Co., Ltd. as lead sponsor, 3 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by TJ Biopharma Co., Ltd.: 20 rows for $5, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email.

Buy: https://specstream.ai/data/clinical-trials/company/tj-biopharma-co-ltd

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 20
- Recruiting or not yet: 3
- Read on: November 19, 2026

## Trials

The 20 newest of 20, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| July 20, 2026 | NCT07715747 | A Study to Evaluate the Safety,Pharmacokinetics,Pharmacodynamics,and Efficacy of TJ037130 in Adult Participants With Advanced Solid Tumors | TJ Biopharma Co., Ltd. | Phase 1 | Recruiting | Solid Tumor, Metastatic Ovary Cancer, Metastatic Gastric Cancer, Metastatic Endometrial Carcinoma | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07715747) |
| March 5, 2026 | NCT07453004 | A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With Acute Gouty... | TJ Biopharma Co., Ltd. | Phase 2 | Recruiting | Acute Gouty Arthritis | 170 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07453004) |
| December 23, 2025 | NCT07300436 | A Study of TJ101 Injection Before and After CMC Change Following Subcutaneous Injection in Healthy Adult Male Subjects in China | TJ Biopharma Co., Ltd. | Phase 1 | Completed | Healthy Adult Males in China | 96 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07300436) |
| October 6, 2025 | NCT07208058 | A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory... | TJ Biopharma Co., Ltd. | Phase 3 | Recruiting | Relapsed/Refractory Rheumatic and Immunologic Disease-associated Haemophagocytic Lymphohistiocytosis | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07208058) |
| June 24, 2025 | NCT07034209 | A Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetic Characteristics, and Immunogenicity of Plonmarlimab in Subjects... | TJ Biopharma Co., Ltd. | Phase 2 | Completed | Hemophagocytic Lymphohistiocytoses | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07034209) |
| June 5, 2025 | NCT07005336 | A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With... | TJ Biopharma Co., Ltd. | Phase 2 | Active not recruiting | Non Small Cell Lung Cancer | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07005336) |
| May 22, 2025 | NCT06984588 | A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With... | TJ Biopharma Co., Ltd. | Phase 2/3 | Active not recruiting | Non Small Cell Lung Cancer | 450 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06984588) |
| February 29, 2024 | NCT06285201 | Study of Felzartamab in Healthy Adult Subjects | TJ Biopharma Co., Ltd. | Phase 1 | Completed | Healthy | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06285201) |
| February 1, 2023 | NCT05709093 | A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in... | TJ Biopharma Co., Ltd. | Phase 3 | Terminated | Myelodysplastic Syndromes(MDS) | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05709093) |
| April 21, 2022 | NCT05338580 | Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors | TJ Biopharma Co., Ltd. | Phase 2 | Withdrawn | First-line Non-small-cell Lung Cancer, First-line Urothelial Carcinoma, Second-line Urothelial Carcinoma, Second-line... | 0 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05338580) |
| December 8, 2021 | NCT05148533 | A Study of Single Drug TJ011133 and Toripalimab Combine Treatment for Advanced Solid Tumor | TJ Biopharma Co., Ltd. | Phase 1/2 | Terminated | Advanced Solid Tumor | 7 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05148533) |
| December 6, 2021 | NCT05145907 | Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid Tumors | TJ Biopharma Co., Ltd. | Phase 2 | Unknown | Triple-negative Breast Cancer, Head and Neck Squamous Cell Carcinoma | 133 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05145907) |
| December 1, 2021 | NCT05140824 | A Study to Evaluate the Safety, Tolerability, and PK Profile of Single and Multiple Doses TJ202 in Patient With Systemic Lupus Erythematosus | TJ Biopharma Co., Ltd. | Phase 1 | Terminated | Systemic Lupus Erythematosus (SLE) | 1 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT05140824) |
| November 18, 2020 | NCT04633057 | A Study to Evaluating the Efficacy and Safety of Recombinant Long-acting Human Growth Hormone (TJ101) in Children With Growth Hormone... | TJ Biopharma Co., Ltd. | Phase 3 | Completed | Pediatric Growth Hormone Deficiency | 168 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04633057) |
| October 23, 2020 | NCT04600817 | A Study to Evaluate the Efficacy and Safety of TJ107 in Lympopenic Patients With Newly Diagnosed Glioblastoma Who Completed Standard... | TJ Biopharma Co., Ltd. | Phase 2 | Unknown | Newly Diagnosed Glioblastoma | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04600817) |
| March 26, 2020 | NCT04322006 | A Phase I/II Study of TJ004309 for Advanced Solid Tumor | TJ Biopharma Co., Ltd. | Phase 1/2 | Completed | Advanced Solid Tumor | 225 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04322006) |
| December 17, 2019 | NCT04202003 | A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and... | TJ Biopharma Co., Ltd. | Phase 1/2 | Completed | Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes(MDS) | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04202003) |
| June 27, 2019 | NCT04001075 | Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of TJ107 in Chinese Patients With Advanced Solid Tumors | TJ Biopharma Co., Ltd. | Phase 1/2 | Completed | Advanced Solid Tumord | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT04001075) |
| May 16, 2019 | NCT03952091 | TJ202, Lenalidomide and Dexamethasone vs. Lenalidomide and Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | TJ Biopharma Co., Ltd. | Phase 3 | Completed | Multiple Myeloma in Relapse, Refractory Multiple Myeloma | 289 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03952091) |
| March 1, 2019 | NCT03860038 | TJ202 Combined With Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma | TJ Biopharma Co., Ltd. | Phase 2 | Completed | Multiple Myeloma in Relapse, Refractory Multiple Myeloma | 113 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT03860038) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 4 |
| Phase 1/2 | 4 |
| Phase 2 | 7 |
| Phase 2/3 | 1 |
| Phase 3 | 4 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 9 |
| Recruiting | 3 |
| Terminated | 3 |
| Unknown | 2 |
| Active not recruiting | 2 |
| Withdrawn | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Multiple Myeloma | 2 |
| Myelodysplastic Syndromes | 2 |
| Carcinoma, Non-Small-Cell Lung | 2 |
| Ovarian Neoplasms | 1 |
| Stomach Neoplasms | 1 |
| Endometrial Neoplasms | 1 |
| Lupus Erythematosus, Systemic | 1 |
| Leukemia, Myeloid, Acute | 1 |
| Recurrence | 1 |
| Lymphohistiocytosis, Hemophagocytic | 1 |
| Triple Negative Breast Neoplasms | 1 |
| Squamous Cell Carcinoma of Head and Neck | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Farm equipment repair companies in the United States](https://specstream.ai/data/businesses/farm-equipment-repair-companies/united-states)
- [Home builders in the United States](https://specstream.ai/data/businesses/home-builders/united-states)
- [Landscape architecture firms in the United States](https://specstream.ai/data/businesses/landscape-architecture-firms/united-states)
- [Nicaraguan restaurants in the United States](https://specstream.ai/data/businesses/nicaraguan-restaurants/united-states)
- [Powder coating companies in the United States](https://specstream.ai/data/businesses/powder-coating-companies/united-states)
- [Sheet metal fabricators in the United States](https://specstream.ai/data/businesses/sheet-metal-fabricators/united-states)
